Major pharmacy group criticizes FTC decision on PBMs

Anthony Vecchione | | Health Exec | Policy & Regulations
Pharmacy

The trade group representing community pharmacists lambasted the FTC’s recent ruling regarding the contracting practices of pharmacy benefit managers (PBMs).

The FTC voted 2-2 on Thursday to not investigate PBMs' competitive impact on contractual provisions, reimbursement adjustments, and other practices affecting drug prices, including those practices that may disadvantage independent or specialty pharmacies.

“Two members of the FTC just let the worst actors in the market off the hook,” B. Douglas Hoey, CEO of the National Community Pharmacists Association (NCPA), said in a prepared statement.

 “After hearing hours of testimony by community pharmacists and patients, all of whom painted the same shocking picture about PBM abuse, and not a single witness there to defend the PBM industry, it is inexplicable that two members of the commission could vote against the study. Their decisions could not possibly have been based on what was heard today," Hoey went on to say.

Hoey added that while he is grateful to FTC Chairwoman Lina Khan for bringing the issue to a vote, he said that NCPA will demand that the topic be revisited as soon as possible.

Anthony Vecchione

Related Content

DEA wants to permanently anchor some COVID-era prescription regulations
FDA regulator examines AI's growing influence in cardiology
FTC, DOJ and HHS release report warning of private equity consolidation in healthcare
Report highlights flaws in FDA rapid approval of Alzheimer drug
FDA announces another recall for surgical devices over safety concerns—7 new injuries reported
Q&A: Vulnerable patients hit hardest by anesthesia reimbursement cuts

Around the web

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.

Cardiovascular Business
FDA announces recall after Philips heart monitor software failed to send alerts—multiple deaths reported

Philips is recalling the software associated with its Mobile Cardiac Outpatient Telemetry devices after certain high-risk ECG events were never routed to trained cardiology technicians as intended. The issue, which lasted for two years, has been linked to more than 100 injuries. 

Cardiovascular Business
Why electrophysiologists needed a champion in Washington

Heart Rhythm Society President Kenneth A. Ellenbogen, MD, detailed a new advocacy group focused on improving EP reimbursements, patient care and access. “If you’re not at the table, you’re on the menu," he said.